SCG opens new cell therapy manufacturing facility in Singapore
20 Jul 2023
Cell TherapyINDImmunotherapyClinical Study
Preview
Source: Pharmaceutical Technology
SCG’s new cell therapy manufacturing facility and research and development centre in Singapore. Credit: SCG Cell Therapy Pte Ltd / PRNewswire.
Biotechnology company SCG Cell Therapy has officially opened its new manufacturing facility and research and development centre at its headquarters in Singapore.
The company’s cGMP [current good manufacturing practice] facility leverages and expands the company’s expertise in advanced manufacturing and off-the-shelf human-induced pluripotent stem cell technology, with the support of the Singapore Economic Development Board.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Embryonic stem cell culturing GlobalData
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Cell therapy for ocular disorders GlobalData
View allCompanies IntelligenceSCG Cell Therapy Pte LtdSCG, INC.Hs&A LtdView all
SCG’s partner hospitals in the Asia Pacific region, North America and Europe will receive cell therapy products from the new facility.
In 2021, SCG joined forces with the Cell Therapy Facility of the Singapore Health Sciences Authority (HSA-CTF) to undergo the validation process for its closed and automated cell therapy manufacturing system.
The system obtained accreditation from the US Food and Drug Administration and the HSA for clinical trials.
SCG Cell Therapy CEO Frank Wang stated: “In line with Singapore’s advanced manufacturing initiatives, the opening of this facility set an important milestone of cell therapy manufacturing advancement in the region.
“As our broad pipeline of cell therapy products progresses to the market, we look forward to further expanding our commercial-scale manufacturing capabilities in Singapore to deliver high-quality and affordable treatment to meet patients’ needs across Singapore, Asia-Pacific and the world.”
SCG is involved in the development of T-cell therapies, antibodies and therapeutic vaccines aimed at combating infections and preventing associated cancers.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.